Insulet — May 8, 2025 release

Extinguished $420 million principal of convertible notes to date • Board of Directors authorized a program to repurchase up to $125 million of common stock through December 31, 2026 to offset dilution from stock-based compensation 2025 Outlook: For the quarter ending June 30, 2025 and year ending December 31, 2025, the Company is providing the following guidance (revenue in constant currency): Q2 2025 Guidance FY 2025 Guidance (as of 5/8/2025) FY 2025 Prior Guidance (as of 2/20/2025) U.S. Omnipod 22% - 25% 18% - 21% 16% - 20% International Omnipod 27% - 30% 27% - 30% 22% - 26% Total Omnipod 23% - 26% 20% - 23% 17% - 21% Drug Delivery 10% - 15% (35)% - (25)% (55)% - (45)% Total 23% - 26% 19% - 22% 16% - 20% Gross Margin ~71% ~70.5% Adjusted Operating Margin ~16.5% ~16.5% Conference Call: Insulet will host a conference call at 4:30 p.m. (Eastern Time) on May 8, 2025 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company’s website at investors.insulet.com, “Events and Presentations,” and will be archived for future reference. The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship